VHCP Management II LLC boosted its holdings in shares of Protagonist Therapeutics Inc (NASDAQ:PTGX) by 57.3% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 426,781 shares of the company’s stock after buying an additional 155,404 shares during the quarter. Protagonist Therapeutics comprises 1.6% of VHCP Management II LLC’s portfolio, making the stock its 14th biggest holding. VHCP Management II LLC owned 1.62% of Protagonist Therapeutics worth $5,168,000 as of its most recent SEC filing.
A number of other institutional investors have also bought and sold shares of PTGX. JPMorgan Chase & Co. grew its position in shares of Protagonist Therapeutics by 99.1% in the second quarter. JPMorgan Chase & Co. now owns 558,729 shares of the company’s stock valued at $6,693,000 after purchasing an additional 278,066 shares during the last quarter. Allianz Asset Management GmbH grew its position in Protagonist Therapeutics by 61.3% during the second quarter. Allianz Asset Management GmbH now owns 124,090 shares of the company’s stock worth $1,503,000 after buying an additional 47,175 shares in the last quarter. Laurion Capital Management LP grew its position in Protagonist Therapeutics by 400.8% during the first quarter. Laurion Capital Management LP now owns 85,641 shares of the company’s stock worth $1,077,000 after buying an additional 68,541 shares in the last quarter. BlackRock Inc. grew its position in Protagonist Therapeutics by 271.6% during the second quarter. BlackRock Inc. now owns 1,017,421 shares of the company’s stock worth $12,321,000 after buying an additional 743,632 shares in the last quarter. Finally, Northern Trust Corp grew its position in Protagonist Therapeutics by 81.0% during the second quarter. Northern Trust Corp now owns 70,340 shares of the company’s stock worth $851,000 after buying an additional 31,477 shares in the last quarter. 73.46% of the stock is currently owned by hedge funds and other institutional investors.
A number of research firms recently weighed in on PTGX. Svb Leerink reissued an “outperform” rating on shares of Protagonist Therapeutics in a research report on Tuesday, August 13th. Nomura reissued a “buy” rating and set a $29.00 target price on shares of Protagonist Therapeutics in a research report on Sunday, August 11th. HC Wainwright set a $23.00 target price on Protagonist Therapeutics and gave the stock a “buy” rating in a research report on Friday, August 2nd. Zacks Investment Research downgraded Protagonist Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, August 13th. Finally, ValuEngine raised Protagonist Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, September 4th. One analyst has rated the stock with a sell rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $19.60.
Protagonist Therapeutics (NASDAQ:PTGX) last released its earnings results on Wednesday, August 7th. The company reported ($1.18) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.90). The firm had revenue of ($8.19) million for the quarter, compared to analyst estimates of $10.77 million. Protagonist Therapeutics had a negative return on equity of 62.50% and a negative net margin of 209.02%. On average, research analysts anticipate that Protagonist Therapeutics Inc will post -2.65 earnings per share for the current year.
In other Protagonist Therapeutics news, insider David Y. Liu sold 3,395 shares of the firm’s stock in a transaction dated Tuesday, August 6th. The shares were sold at an average price of $8.85, for a total transaction of $30,045.75. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Dinesh V. Ph D. Patel sold 10,792 shares of the firm’s stock in a transaction dated Tuesday, August 6th. The stock was sold at an average price of $8.85, for a total transaction of $95,509.20. The disclosure for this sale can be found here. 14.20% of the stock is owned by company insiders.
About Protagonist Therapeutics
Protagonist Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops peptide-based product candidates to address unmet medical needs in hematology and gastroenterology. The company is developing PTG-300, an injectable hepcidin mimetic that is in Phase II clinical trial for the treatment of patients with beta-thalassemia by targeting the chronic anemia; PTG-200, an antagonist peptide product candidate, which has completed Phase I clinical trial to treat inflammatory bowel disease (IBD); and PN-943, an oral, alpha-4-beta-7 specific integrin antagonist that is in Phase I clinical trial for treating IBD.
Want to see what other hedge funds are holding PTGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Protagonist Therapeutics Inc (NASDAQ:PTGX).
Receive News & Ratings for Protagonist Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.